A study looking into a CP-specific prognostic biomarker for resistance in epithelial ovarian cancer suggested that MEK1, involved in the MAPK cascade and the greater EGFR pathway by enhancing proliferation and anti-apoptotic signals, is a strong candidate [1]. Here, MAP2K1 is linked to ovarian carcinoma.